Mathew Garnett

Founder

Senior Group Leader at the Wellcome Sanger Institute
20+ years’ experience in genomics and cancer therapeutics
Developer of leading, widely-used cancer therapeutics resources (inc. DepMap and GDSC)
Co-discoverer of:
- BRAF mutations in cancer
- Werner helicase as a target in MSI tumours
Open Targets Sanger Scientific Lead

Adrian Ibrahim